{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:52:33Z","timestamp":1794671553182,"version":"4.9.1"},"reference-count":14,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2004,6,21]],"date-time":"2004-06-21T00:00:00Z","timestamp":1087776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetic Medicine"],"published-print":{"date-parts":[[2004,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>HbA<jats:sub>1c<\/jats:sub> is recommended for monitoring glycaemic control and quantifying the risk of complications in patients with diabetes. National guidelines for treatment of patients with diabetes in UK specify that HbA<jats:sub>1c<\/jats:sub> measurements should be Diabetes Control and Complications Trial (DCCT)\u2010aligned i.e. comparable to the DCCT and UK Prospective Diabetes Study (UKPDS).<\/jats:p><jats:p>The IFCC reference method for HbA<jats:sub>1c<\/jats:sub> will be introduced in Europe in December 2003 for calibration of all laboratory and POCT (point of care testing) methods for HbA<jats:sub>1c<\/jats:sub> following the recent EC \u2018In Vitro Diagnostic\u2019 (IVD) directive. This reference method involves measurement of HbA<jats:sub>1c<\/jats:sub> and HbA<jats:sub>0<\/jats:sub> by electron\u2010spray ionisation\u2010mass spectrometry or capillary electrophoresis with the reference range approximately 2% HbA<jats:sub>1c<\/jats:sub> lower than the corresponding range from the DCCT. However, this EC IVD directive will not change reporting of DCCT\u2010aligned HbA<jats:sub>1c<\/jats:sub> in the UK.<\/jats:p><jats:p>Professionals involved in the care of patients with diabetes in the UK met with Dr Sue Roberts in London in July 2003. It was decided that in the UK DCCT\u2010aligned HbA<jats:sub>1c<\/jats:sub> will continue to be reported from December 2003 for patient care and that laboratories currently reporting non\u2010aligned DCCT HbA<jats:sub>1c<\/jats:sub> should change to reporting DCCT\u2010aligned results as soon as possible. It was considered important for diabetes care in the UK that the reporting of HbA<jats:sub>1c<\/jats:sub> should not fragment. The UK HbA<jats:sub>1c<\/jats:sub> Standardization Committee was set up to hold \u2018a watching brief\u2019 on HbA<jats:sub>1c<\/jats:sub> especially with relation to reporting of HbA<jats:sub>1c<\/jats:sub> in other countries.<\/jats:p>","DOI":"10.1111\/j.1464-5491.2004.01311.x","type":"journal-article","created":{"date-parts":[[2004,11,15]],"date-time":"2004-11-15T12:33:40Z","timestamp":1100522020000},"page":"673-676","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Introduction of IFCC reference method for calibration of HbA<sub>1c<\/sub>: implications for clinical care"],"prefix":"10.1111","volume":"21","author":[{"given":"S.","family":"Manley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. G.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,6,21]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long\u2010term complications of insulin\u2010dependent diabetes mellitus: the Diabetes Control and Complications Trial","volume":"329","author":"DCCT Study Group.","year":"1993","journal-title":"N Eng J Med"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405"},{"key":"e_1_2_8_5_2","first-page":"671","article-title":"diabetes (UKPDS 56)","volume":"101","author":"Stevens RJ","year":"2001","journal-title":"Clin Sci"},{"key":"e_1_2_8_6_2","volume-title":"NICE Clinical Guideline G.","author":"National Institute for Clinical Excellence.","year":"2002"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00252410"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2002.016"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/43.10.1944"},{"key":"e_1_2_8_10_2","first-page":"67","article-title":"Evaluation of a reference material for glycated hemoglobin","volume":"34","author":"Weykamp CW","year":"1996","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"e_1_2_8_11_2","first-page":"243","article-title":"A re\u2010evaluation of glycohemoglobin standardization: the Italian experience with 119 laboratories and 12 methods","volume":"35","author":"Mosca A","year":"1997","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"e_1_2_8_12_2","doi-asserted-by":"crossref","unstructured":"HoelzelW WeykampC JeppssonJ\u2010O MiedemaK BarrJ GoodallIet al.on behalf of the IFCC Working Group on HbA1cStandardization.The IFCC reference system for the measurement of HbA1c in human blood and the national standardization schemes in the USA Japan and Sweden\u2014a method comparison study.Clin Chem2004;50:166\u2013174.","DOI":"10.1373\/clinchem.2003.024802"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1258\/0004563001901506"},{"key":"e_1_2_8_14_2","first-page":"78","article-title":"Standardisation of glycated haemoglobin","volume":"39","author":"Marshall SM","year":"2002","journal-title":"Ann Clin Biochem"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.11.2110"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-5491.2004.01311.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-5491.2004.01311.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-5491.2004.01311.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:29:08Z","timestamp":1697185748000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-5491.2004.01311.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,21]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["10.1111\/j.1464-5491.2004.01311.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-5491.2004.01311.x","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,21]]},"assertion":[{"value":"2004-06-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}